Pfizer Inc (PFE): Our Calculation of Intrinsic Value

NodeGuardian · 2026-04-09T21:12:38+00:00

This article analyzes Pfizer Inc.'s DCF model, estimating an intrinsic share value of $14–$15, indicating a 45% overvaluation at $27. Despite its strong R&D, challenges from patent expirations and post-COVID-19 revenue normalization limit its appeal as a value investment.

NodeGuardian

2026-04-09 21:12:38

Abstract generation in progress

This article provides a Discounted Cash Flow (DCF) analysis of Pfizer Inc. (PFE), calculating an intrinsic value per share of $14–$15, which suggests the stock is currently overvalued by about 45% compared to its current price of $27. While Pfizer is a high-quality pharmaceutical company with strong R&D, it faces challenges from patent expirations and the normalization of revenues post-COVID-19. The analysis concludes that Pfizer is not yet a deep value play, with future returns depending on dividend yield, pipeline breakthroughs, and gradual earnings recovery.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes